Lord, Abbett & Co’s Integra LifeSciences IART Stock Holding History

Lord, Abbett & Co’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,328,701	Closed	-$29.2M	–	545
2025 Q1	$29.2M	Sell	1,328,701 -3,330	-0.2%	-$78.3K	0.1%	227
2024 Q4	$30.2M	Buy	1,332,031 +618,773	+87%	+$13.5M	0.1%	255
2024 Q3	$13M	Sell	713,258 -105,239	-13%	-$2.44M	0.04%	373
2024 Q2	$23.9M	Buy	+818,497	New	+$24.3M	0.08%	293
2018 Q4	–	Sell	-650,879	Closed	-$42.9M	–	793
2018 Q3	$42.9M	Buy	650,879 +77,612	+14%	+$4.82M	0.12%	288
2018 Q2	$36.9M	Buy	+573,267	New	+$35.5M	0.11%	305
2016 Q4	–	Sell	-854,578	Closed	-$35.3M	–	911
2016 Q3	$35.3M	Sell	854,578 -203,698	-19%	-$8.53M	0.11%	302
2016 Q2	$42.2M	Buy	1,058,276 +242,270	+30%	+$8.72M	0.13%	245
2016 Q1	$27.5M	Buy	+816,006	New	+$25.4M	0.09%	348

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lord, Abbett & Co's IART Position: Q2 2025 in Review

Lord, Abbett & Co sold out of Integra LifeSciences (IART) in Q2 2025, closing a stake of 1,328,701 shares — an estimated $29.2M sold.

Lord, Abbett & Co first reported a position in IART in Q1 2016 and held it in 9 quarters. The position peaked at $42.9M in Q3 2018. 208 funds tracked by Wall St. Rank hold IART as of Q2 2025.

Lord, Abbett & Co reported no remaining Integra LifeSciences position as of Q2 2025 after selling out during the quarter.
Lord, Abbett & Co sold 1,328,701 Integra LifeSciences shares in Q2 2025, an estimated $29.2M.
Lord, Abbett & Co first reported a position in Integra LifeSciences in Q1 2016 and held it in 9 quarters.
Lord, Abbett & Co's Integra LifeSciences position peaked at $42.9M in Q3 2018.
208 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2025.

Based on Lord, Abbett & Co's 13F filing for Q2 2025, filed 14 Aug 2025.